Vasudha Sehgal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11643080/publications.pdf

Version: 2024-02-01

17 papers	1,656 citations	687363 13 h-index	940533 16 g-index
17	17	17	4319
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clinical Cancer Research, 2021, 27, 4449-4449.	7.0	O
2	Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature, 2020, 578, 306-310.	27.8	259
3	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Research, 2018, 78, 3233-3242.	0.9	69
4	Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein–Barr virus DNA load. Proteomics - Clinical Applications, 2017, 11, 1600090.	1.6	7
5	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 1713-1724.	7.0	69
6	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. Npj Systems Biology and Applications, 2015, 1, 15001.	3.0	3
7	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 448-459.	7.0	48
8	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Research, 2015, 25, 257-267.	5.5	94
9	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. PLoS ONE, 2015, 10, e0140072.	2.5	9
10	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 \hat{l}_{\pm} and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.9	161
11	Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clinical Cancer Research, 2014, 20, 2740-2750.	7.0	14
12	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.9	59
13	$2\hat{a}\in^2$ -OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	12.8	103
14	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	16.8	252
15	A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. Journal of Hepatology, 2014, 60, 1203-1211.	3.7	99
16	Network Motifs in JNK Signaling. Genes and Cancer, 2013, 4, 409-413.	1.9	47
17	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363